CN105713876A - CIK (cytokine-induced killer) cell culture medium and application thereof - Google Patents
CIK (cytokine-induced killer) cell culture medium and application thereof Download PDFInfo
- Publication number
- CN105713876A CN105713876A CN201610185670.4A CN201610185670A CN105713876A CN 105713876 A CN105713876 A CN 105713876A CN 201610185670 A CN201610185670 A CN 201610185670A CN 105713876 A CN105713876 A CN 105713876A
- Authority
- CN
- China
- Prior art keywords
- culture medium
- concentration
- cik
- cell
- cik cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2327—Interleukin-27 (IL-27)
Abstract
The invention relates to a CIK (cytokine-induced killer) cell culture medium. The CIK cell culture medium is characterized by comprising PPP (poor platelet plasma), IL-2 (interleukin-2), IL-12 (interleukin-12), IL-27 (interleukin-27) and a serum-free basal culture medium. The IL-27 is linked with the IL-2 and the IL-12, so that toxic and side effects caused by large doses of cytokines can be reduced, the CIK amplification rate can be increased, and especially the killing activity of CD3<+> and CD56<+> CIK cells is improved.
Description
Technical field
The present invention relates to biological technical field, particularly to a kind of CIK cell culture medium and application thereof.
Background technology
Cellular immunotherapy be a kind of emerging, there is the brand-new antitumour treatments of significant curative effect, compensate for the drawback of traditional operation, radiotherapy, chemotherapy, it is acknowledged as a kind for the treatment of means active, the most rising in 21st century combined therapy of tumour pattern, the currently the only treatment means being hopeful complete tumors destroyed cell in the Ye Shi world.Immunocyte refers to participation immunne response or the cell relevant to immunne response, including lymphocyte, dendritic cell, Monocytes/Macrophages, granulocyte, mastocyte etc..
CIK (cytokine-inducedkiller, Chinese name: the killing cell of [autogenous cell immunotherapy] cytokine profiles induction) it is the mononuclearcell a group foreign cell group that cultivates acquisition under the effect of CD 3-resisting monoclonal antibody and cytokine profiles, wherein CD3+, CD56+Lymphocyte is main effects cell.CIK can direct killing tumor cell and virus infected cell；Inducing apoptosis of tumour cell；Suppress or killing tumor cell by discharging a large amount of inflammatory cytokine.CIK cell has that growth rate is fast, kill tumor activity height, to kill tumor spectrum wide, multidrug resistant tumor cell is sensitive equally, to features such as normal bone marrow hematogenesis precursor cytotoxicity are little, it is that the tumor cell killing activity having now been found that is strong, it is suitable for a kind of desirably effector lymphocyte of clinical practice, but this effector lymphocyte is extremely rare in normal peripheral blood, is only 1%～5%.As can be seen here, with regard to immune cell therapy, how to obtain necessary requirement sufficient amount of, that immunocompetence is strong effector lymphocyte is to ensure that therapeutic effect.
CIK cell can by external evoked and breed in a large number, conventional CIK preparation method is to add in culture fluid by the PERIPHERAL BLOOD MONONUCLEAR CELL separated, carry out stimulating induction, a number of CIK cell of final acquisition, but the final CD3 obtained by adding cell growth factor+And CD56+CIK cell quantity and killing activity are all not ideal enough.
Summary of the invention
The technical problem to be solved is, there is amplification efficiency difference for CIK cell culture medium in prior art, the defects such as cell killing activity is low, it is provided that one can improve CIK cell amplification efficiency, especially improve CD3+And CD56+CIK cell quantity, improves the CIK cell culture medium of killing activity.
The technical solution adopted for the present invention to solve the technical problems is: provide a kind of CIK cell culture medium, including PPP, IL-2, IL-12, IL-27 and serum-free basal medium.
In CIK cell culture medium provided by the invention, described serum-free basal medium is AIM-V culture medium.
In CIK cell culture medium provided by the invention, in described serum-free basal medium, the volume fraction of PPP is 3～5%, and the concentration of IL-2 is the concentration that concentration is 800～1200IU/ml, IL-27 of 800～1200IU/ml, IL-12 is 5～30ng/ml.
In CIK cell culture medium provided by the invention, in described serum-free basal medium, the concentration of IL-27 is 15～25ng/ml.
In CIK cell culture medium provided by the invention, in described serum-free basal medium, the volume fraction of PPP is 4%, and the concentration of IL-2 is the concentration that concentration is 1000IU/ml, IL-27 of 1000IU/ml, IL-12 is 18ng/ml.
The present invention protects the application in CIK cell incubation of the above-mentioned CIK cell culture medium further.
Implement CIK cell culture medium provided by the invention, it is possible to reach following beneficial effect: adopt IL-27 to combine IL-2 and IL-12, can not only reduce the toxic and side effects that heavy dose of cytokine is brought, and the amplification rate of CIK can be improved, especially CD3+And CD56+CIK cell, improves its killing activity.
Detailed description of the invention
CIK cell culture medium provided by the invention, including PPP (PoorPlateletPlasma, platelet-poor plasma), IL-2 (Interleukin, interleukin-22), IL-12 (Interleukin, interleukin 12) and IL-27 (Interleukin, interleukin-22 7)；Preferably, serum-free basal medium is AIM-V culture medium, is purchased from Gibco company of the U.S..
Wherein, IL-27, it is possible to remarkably promote the propagation of CIK cell, and initial CD4 can be induced+T cell expresses IL-12 beta 2 receptor so that it is obtain the reactivity to IL-12, and the collaborative IL-12 inducer T lymphocyte of IL-27 produces IFN-γ.
The peptide molecule that IFN-γ is had several functions by family forms, and has suppression virus replication, suppresses the effect such as tumor growth and immunomodulating, plays an important role in Cellular Immunity and humoral immunization.IFN-γ can express high-affinity IL-2R thus activating T cell by induced monocyte release cells factor IL-12, promotes the propagation of CIK cell.
And IL-27 combines IL-2 and can be obviously promoted CIK cell maturation, shorten CIK cell cultivation cycle, improve CIK cell and kill ability, promote the expression of the horizontal high expressed of CIK cell IFN-γ and TNF α (TumorNecrosisFactor, tumor necrosis factor-alpha).
To sum up, IL-27 combines IL-12 and IL-2 cultivation can reduce the toxic and side effects that heavy dose of cytokine is brought on the one hand, can obtain the CIK cell of sufficient amount and function, especially CD3 on the other hand+And CD56+CIK cell；Meanwhile, it is capable to reduce the using dosage of cytokine.
PPP can provide certain nutritional support for cell, and can improve amplification rate and the Maturity of CIK cell, improves the activity of CIK cell.
Preferably, in serum-free basal medium, the volume fraction of PPP is 3～5%, and the concentration of IL-2 is the concentration that concentration is 800～1200IU/ml, IL-27 of 800～1200IU/ml, IL-12 is 5～30ng/ml；It is further preferable that the concentration of IL-27 is 15～25ng/ml.
Further, the CIK cell culture medium provided by the invention application in cultivating CIK cell process, comprise the following steps
S1, acquisition mononuclearcell；
S2, with CIK cell derivant, mononuclearcell is carried out inducing culture 18～36 hours, to gathering in the crops primary CIK cell；
Wherein, CIK cell derivant includes IFN-γ (Interferon-γ, IFN-γ), anti-CD49d McAb and IL-1 α (Interleukin, interleukin-11 α)；Preferably, in derivant A, the concentration of IFN-γ is 800～1200IU/ml, and the concentration of anti-CD49d McAb is the concentration of 10-150ng/ml, IL-1 α is 10-50 μ g/ml；
S3, adopt CIK cell culture medium provided by the invention primary CIK cell is carried out amplification in vitro cultivate 7～21 days, within every 2～3 days, add CIK cell culture medium, to keep PPP in CIK cell culture medium, IL-2, IL-12 and IL-27 concentration constant.
In order to make the purpose of the present invention, technical scheme and advantage clearly understand, below in conjunction with embodiment, the present invention is further elaborated.Should be appreciated that specific embodiment described herein is only in order to explain the present invention, is not intended to limit the present invention.
Embodiment 1
CIK cell culture medium provided by the invention, comprises the following steps:
S1a, from peripheral blood, isolate mononuclearcell；
S11a, aseptic condition gather healthy volunteer peripheral blood 20ml, anticoagulant heparin, in GMP Clean Operating Lab, 20 DEG C, centrifugal 1000g × 10min, draws upper plasma and is placed in another aseptic 50ml centrifuge tube, and blood plasma is centrifuged in rear 56 DEG C of water baths to place 30min standby, add D-PBS buffer and the hemocyte layer dilution proportion with 1:1, piping and druming mixing.
S12a, employing Ficoll density－gradient centrifuga－tion method separation human peripheral blood single nucleus cell；
The lymphocyte separation medium of 25ml is filled respectively with two 50ml centrifuge tubes, slowly along centrifuge tube tube wall, the blood after dilution is added to lymphocyte separation medium upper strata with Sterile pipette, the volume ratio forming obvious interface, dilute blood and lymphocyte separation medium is 1:1.
S13a, high speed low temperature centrifugal machine, 20 DEG C, centrifugal, 800g × 30min；
In S14a, centrifugal rear centrifuge tube, liquid is divided into four layers, is red blood cell layer, lymphocyte separation medium layer, tunica albuginea layer and plasma layer from down to up respectively.Namely PERIPHERAL BLOOD MONONUCLEAR CELL is positioned at tunica albuginea layer, is moved in another 50ml sterile centrifugation tube by this layer with Sterile pipette.
S15a, washing tunica albuginea confluent monolayer cells three times, fill it up with 50ml with D-PBS solution, fully mixing tunica albuginea confluent monolayer cells, 20 DEG C, centrifugal: 1000g × 10min, abandoning supernatant, it is thus achieved that PERIPHERAL BLOOD MONONUCLEAR CELL, repeated washing three times.
After S16a, centrifuge washing, sopping up supernatant, by GT-T551 culture medium by cell piping and druming mixing, a small amount of cell of sucking-off counts, and adjusting cell concentration is 1 × 106Individual/ml, plants in, in the coated 175cm culture bottle of CD3-Ab and FN, being added the appropriate autoserum separated, for CIK cell in vitro inducing culture.
S2a, PERIPHERAL BLOOD MONONUCLEAR CELL is carried out inducing culture to changing into CIK cell；
The mononuclearcell obtained in step S1a is resuspended in AIM-V culture medium, and adds CIK cell derivant, be placed in 37 DEG C, 5%CO2Incubator is cultivated 24 hours；Wherein in CIK cell derivant, the concentration of IFN-γ is 1000IU/ml, and the concentration of anti-CD49d McAb is the concentration of 80ng/ml, IL-1 α is 30 μ g/ml；
S3a, CIK cell is carried out amplification in vitro cultivation；
CIK cell culture medium provided by the invention is added in CIK cell, wherein, in AIM-V culture medium, the volume fraction of PPP is 4%, the concentration that the concentration that concentration is 1000IU/ml, IL-12 is 1000IU/ml and IL-27 of IL-2 is 18ng/ml, within every 2～3 days, add containing PPP, IL-2, IL-12 and IL-27 fresh CIK cell culture medium, cultivate 21 days.
Wherein, the acquisition process of PPP is: take the peripheral blood after 100ml anticoagulant processes, peripheral blood is added separately in the sterile centrifugation tube of 4 50ml, 300g is centrifuged 10min, being transferred to by all of upper plasma in 2 new sterile centrifugation tube, 56 DEG C of water-bath inactivation 30min, after the centrifugal 10min of 400g, collecting upper strata yellow liquid and PPP, 4 DEG C store for future use.
Embodiment 2
Being different in that with embodiment 1, in this embodiment, the composition of the CIK cell culture medium adopted is:
AIM-V culture medium, PPP volume fraction be 3%, the concentration of IL-2 is the concentration that concentration is 800IU/ml, IL-27 of 800IU/ml, IL-12 is 5ng/ml.
Embodiment 3
Being different in that with embodiment 1, in this embodiment, the composition of the CIK cell culture medium adopted is:
AIM-V culture medium, PPP volume fraction be 5%, the concentration of IL-2 is the concentration that concentration is 1200IU/ml, IL-27 of 1200IU/ml, IL-12 is 30ng/ml.
Embodiment 4
Being different in that with embodiment 1, in this embodiment, the composition of the CIK cell culture medium adopted is:
AIM-V culture medium, PPP volume fraction be 4%, the concentration of IL-2 is the concentration that concentration is 1000IU/ml, IL-27 of 1000IU/ml, IL-12 is 15ng/ml.
Embodiment 5
Being different in that with embodiment 1, in this embodiment, the composition of the CIK cell culture medium adopted is:
AIM-V culture medium, PPP volume fraction be 4%, the concentration of IL-2 is the concentration that concentration is 1000IU/ml, IL-27 of 1000IU/ml, IL-12 is 25ng/ml.
With method for resuscitation, there is significant beneficial effect for verifying that microencapsulation immunocyte provided by the invention is frozen further, following experiment is set and is verified.
CIK cell after detection group 1～5 amplification that the corresponding embodiment of the present invention 1～5 obtains respectively；
The CIK cell that matched group is obtained by existing CIK cell culture medium, particularly as follows: the PERIPHERAL BLOOD MONONUCLEAR CELL serum-free basal medium of collection is adjusted concentration is 1 × 106U/ml, the IFN-γ adding 1000U/ml on the 1st day；
Subsequently culture fluid is placed in 37 DEG C, CO2Concentration is 5%, humidity be 100% constant incubator in cultivate 24 hours；It is subsequently added IL-1 α, IL-2 and CD3 monoclonal antibody so that IL-1 α, IL-2 and CD3 monoclonal antibody final concentration respectively 300U/ml, 1000U/ml and 500U/ml in the medium；
Then continue at 37 DEG C, CO2Concentration is 5%, humidity be 100% constant incubator in cultivate, every 3 days add culture medium, make cell concentration be maintained at 1 × 106The concentration of U/ml, IL-1 α and CD3 monoclonal antibody is kept at 300U/ml, 1000U/ml and 500U/ml.
1, the mensuration of cell proliferation multiple
Counting after the CIK cell Trypan Blue of acquirement with hematimeter, by current total cellular score divided by the mononuclearcell number before cultivating, numerical value is the amplification times of cell again.With the method can the proliferative conditions of dynamic observation of cell, concrete condition is in Table 1.
Table 1
| Cultivated days | 0 | 7 | 14 | 21 |
| Detection group 1 | 1 | 24.38±4.33 | 108.36±5.46 | 175.10±7.42 |
| Detection group 2 | 1 | 20.49±4.45 | 98.27±5.57 | 155.09±7.51 |
| Detection group 3 | 1 | 23.47±4.24 | 105.48±5.37 | 171.21±7.33 |
| Detection group 4 | 1 | 28.38±4.46 | 110.45±5.57 | 180.10±7.34 |
| Detection group 5 | 1 | 31.27±4.41 | 121.51±5.28 | 188.29±7.36 |
| Matched group | 1 | 12.47±4.12 | 52.37±5.27 | 83.42±6.77 |
Testing result: result shows, along with the prolongation of incubation time, the increased times of two groups of cells is all improving, but the increased times that detection group 1～5 is on each timing node is significantly higher than detection group, and the amplification times of two groups of cells all reached summit at 21 days.
2, iuntercellular phenotype analytical compares
Taking two groups of CIK cell at the 0th, 7,14,21 days respectively, make cell suspension, adjusting cell concentration after washing is 1 × 105U/ml, add the monoclonal antibody of labelling, hatch in room temperature dark place 15 minutes, wash away Excess antibody, using flow cytomery, result is in Table 2.
Table 2
Testing result: along with the prolongation of incubation time, CD3+ cell and the ratio of CD3+CD56+ cell in two groups of cells are all increasing, and difference between the two is not statistically significant；CD3+CD4+ cell proportion in two groups of cells reduces as time went on, and from the 7th day, the difference between two groups was statistically significant；CD3+CD56+ cell proportion aspect in two groups of cells, detection group is above matched group and difference statistically significant (P < 0.01) at each timing node.This shows that both of which can be greatly improved the ratio of CD+ cell, but in the CD3+CD56+ cell proportion in CIK cell, detection group to be substantially better than matched group.
3, mtt assay tests two groups of cells in vitro killing activities
Taking the logarithm the K562 tumor cell line of trophophase, re-suspended cell concentration is 1 × 105Individual/ml, 5 × 104Individual/ml, 2.5 × 104Individual/ml, every hole 100 μ l is laid in 96 level land, hole plates, is placed in 37 DEG C, CO2Concentration is 5%, humidity be 100% constant incubator in cultivate 24 hours stand-by；
It is 1 × 10 by cultivating two groups of CIK cell of 14 days resuspended6Individual/ml, add in aforementioned 96 orifice plates, make effect target than for 10:1,20:1 and 40:1, each concentration respectively sets 4 multiple holes, and set two groups of CIK cell not reacting with tumor cell as effector lymphocyte's blank, after co-culturing 48 hours, every hole adds MTT solution (5mg/ml) 20 μ l, after continuing cultivation 4 hours, being centrifuged and abandon supernatant, every hole adds DMSO100 μ l, measures absorption values in 570nm place, calculate killing rate, killing rate computing formula: killing rate=[1-(test hole A value-effector lymphocyte's A value)/target cell control wells A value] × 100%
Table 3
Testing result: under different effect targets is compared to and uses, the killing rate of tumor cell line is above matched group by detection group, and the difference between different effect target ratios is statistically significant, imitates target than under condition in difference, the killing rate of experimental group is substantially better than matched group, and difference is statistically significant.
Above embodiments of the invention are described; but the invention is not limited in above-mentioned detailed description of the invention; above-mentioned detailed description of the invention is merely schematic; rather than it is restrictive; those of ordinary skill in the art is under the enlightenment of the present invention; without departing under present inventive concept and scope of the claimed protection situation, it may also be made that a lot of form, these belong within the protection of the present invention.
Claims (10)
1. a CIK cell culture medium, it is characterised in that include PPP, IL-2, IL-12, IL-27 and serum-free basal medium.
2. CIK cell culture medium according to claim 1, it is characterised in that described serum-free basal medium is AIM-V culture medium.
3. CIK cell culture medium according to claim 2, it is characterised in that in described serum-free basal medium, the volume fraction of PPP is 3～5%, the concentration of IL-2 is the concentration that concentration is 800～1200IU/ml, IL-27 of 800～1200IU/ml, IL-12 is 5～30ng/ml.
4. CIK cell culture medium according to claim 3, it is characterised in that in described serum-free basal medium, the volume fraction of PPP is 4%, and the concentration of IL-2 is the concentration that concentration is 1000IU/ml, IL-27 of 1000IU/ml, IL-12 is 18ng/ml.
5. CIK cell culture medium according to claim 3, it is characterised in that in described serum-free basal medium, the volume fraction of PPP is 3%, and the concentration of IL-2 is the concentration that concentration is 800IU/ml, IL-27 of 800IU/ml, IL-12 is 5ng/ml.
6. CIK cell culture medium according to claim 3, it is characterised in that in described serum-free basal medium, the volume fraction of PPP is 5%, and the concentration of IL-2 is the concentration that concentration is 1200IU/ml, IL-27 of 1200IU/ml, IL-12 is 30ng/ml.
7. CIK cell culture medium according to claim 3, it is characterised in that in described serum-free basal medium, the concentration of IL-27 is 15～25ng/ml.
8. CIK cell culture medium according to claim 7, it is characterised in that in described serum-free basal medium, the concentration of IL-27 is 15ng/ml.
9. CIK cell culture medium according to claim 8, it is characterised in that in described serum-free basal medium, the concentration of IL-27 is 25ng/ml.
10. the CIK cell culture medium as described in any one of claim 1～9 application in CIK cell incubation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610185670.4A CN105713876A (en) | 2016-03-29 | 2016-03-29 | CIK (cytokine-induced killer) cell culture medium and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610185670.4A CN105713876A (en) | 2016-03-29 | 2016-03-29 | CIK (cytokine-induced killer) cell culture medium and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105713876A true CN105713876A (en) | 2016-06-29 |
Family
ID=56158381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610185670.4A Pending CN105713876A (en) | 2016-03-29 | 2016-03-29 | CIK (cytokine-induced killer) cell culture medium and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105713876A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106754700A (en) * | 2016-12-23 | 2017-05-31 | 西安东澳生物科技有限公司 | A kind of preparation method of antitumor adoptive immunity competent cell CIK |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008092445A2 (en) * | 2007-01-30 | 2008-08-07 | Deutsches Rheuma-Forschungszentrum Berlin | Method for modulating the immune response by activating or inactivating the notch and/or stat4 signal path |
| EP1589998B1 (en) * | 2002-12-31 | 2011-04-27 | Schering Corporation | IL-27 and IL-2 for use in the treatment of cancer |
| CN102625832A (en) * | 2009-08-24 | 2012-08-01 | 贝勒医学院 | Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses |
| CN103923880A (en) * | 2014-05-08 | 2014-07-16 | 成都百赛泰科生物科技有限公司 | Efficient multiplication CTL preparation method killing tumors in targeted mode |
| CN105154397A (en) * | 2015-07-09 | 2015-12-16 | 深圳爱生再生医学科技有限公司 | Preparation method of CIK (cytokine-induced killer) cells |
| CN105154398A (en) * | 2015-07-17 | 2015-12-16 | 深圳爱生再生医学科技有限公司 | CIK (cytokine-induced killer) and preparation method thereof |
| CN105316290A (en) * | 2015-10-22 | 2016-02-10 | 深圳爱生再生医学科技有限公司 | Preparation method of CIK in three-dimensional environment |
| CN105349489A (en) * | 2015-12-07 | 2016-02-24 | 广州赛莱拉干细胞科技股份有限公司 | Culture method of CIK cell |
-
2016
- 2016-03-29 CN CN201610185670.4A patent/CN105713876A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1589998B1 (en) * | 2002-12-31 | 2011-04-27 | Schering Corporation | IL-27 and IL-2 for use in the treatment of cancer |
| WO2008092445A2 (en) * | 2007-01-30 | 2008-08-07 | Deutsches Rheuma-Forschungszentrum Berlin | Method for modulating the immune response by activating or inactivating the notch and/or stat4 signal path |
| CN102625832A (en) * | 2009-08-24 | 2012-08-01 | 贝勒医学院 | Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses |
| CN103923880A (en) * | 2014-05-08 | 2014-07-16 | 成都百赛泰科生物科技有限公司 | Efficient multiplication CTL preparation method killing tumors in targeted mode |
| CN105154397A (en) * | 2015-07-09 | 2015-12-16 | 深圳爱生再生医学科技有限公司 | Preparation method of CIK (cytokine-induced killer) cells |
| CN105154398A (en) * | 2015-07-17 | 2015-12-16 | 深圳爱生再生医学科技有限公司 | CIK (cytokine-induced killer) and preparation method thereof |
| CN105316290A (en) * | 2015-10-22 | 2016-02-10 | 深圳爱生再生医学科技有限公司 | Preparation method of CIK in three-dimensional environment |
| CN105349489A (en) * | 2015-12-07 | 2016-02-24 | 广州赛莱拉干细胞科技股份有限公司 | Culture method of CIK cell |
Non-Patent Citations (5)
| Title |
|---|
| NAOKO KANDA等: "IL-12, IL-23, and IL-27 enhance human b-defensin-2 production in human keratinocytes", 《EUROPEAN JOURNAL OF IMMUNOLOGY》 * |
| 丛丽媛等: "IFN-γ与IL-12诱导CIK细胞生物学活性的比较研究", 《现代免疫学》 * |
| 段玉青: "白细胞介素-27促进CIK细胞增殖及杀伤功能实验研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 秦莉等: "IL-12对CIK细胞体外增殖及细胞毒活性影响的研究", 《国际免疫学杂志》 * |
| 郑秀娟等: "两种不同成分培养基制备CIK细胞的生物学特征", 《中国肿瘤生物治疗杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106754700A (en) * | 2016-12-23 | 2017-05-31 | 西安东澳生物科技有限公司 | A kind of preparation method of antitumor adoptive immunity competent cell CIK |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103756963B (en) | A kind of method of amplification in vitro NK cell | |
| CN105087487B (en) | A kind of method of efficient amplification CIK | |
| CN105238754B (en) | A kind of high proliferation power and the extracorporeal culturing method of High Fragmentation power NK cell | |
| CN107326008A (en) | A kind of method of high-purity amplifying natural killer cell efficient from peripheral blood | |
| CN105925527A (en) | Kit for preparing NK cells and application method thereof | |
| CN102268405A (en) | Method for auto NK (Natural Killer) cell in-vitro activation and amplification culture and special culture medium thereof | |
| CN105087488A (en) | Preparation method and application of DC-CIK cell induced by tumor antigen | |
| CN104894065A (en) | NK (natural killer) cell culture medium and culture method of NK cell | |
| CN103642752A (en) | Preparation method of human CD3+CD8+CIK (cytokine induced killer) cells | |
| CN104815323A (en) | Dendrite cell tumor vaccine and preparation method thereof | |
| CN104711224A (en) | In-vitro culture method for increasing human Vdelta2 T cell amplification efficiency and application thereof | |
| EP2878666B1 (en) | Industrial preparation of natural killer cells (nks) and injection using human allogeneic karyocytes | |
| CN104073467A (en) | Preparing method of human DCCIK immunocompetent cell | |
| CN110272871B (en) | Composition for stimulating and inducing expansion of mononuclear cells into gamma delta T cells and application thereof | |
| CN106190976A (en) | A kind of NK cell culture medium and the cultural method of NK cell | |
| CN105907714A (en) | Improved method for cultivating NK (natural killer) cells | |
| CN104894072A (en) | Preparation method and application of autologous natural killer cell proliferation | |
| CN101182488A (en) | New use of mesenchyma stem cell | |
| CN107475194B (en) | The application of NKT cell culture mediums, cultural method and the two | |
| CN107523541B (en) | It is a kind of with atractylenolide be promote multiplication agent CIK cell culture medium | |
| CN104818249B (en) | A kind of enhanced CIK cell preparation and preparation method thereof | |
| CN109486758A (en) | A kind of external efficient amplification reagent of peripheral blood NK cell and operating instruction | |
| CN104911148A (en) | Human immunocompetent cell DC-CIK cytomedicine and effective preparation method thereof | |
| CN105713876A (en) | CIK (cytokine-induced killer) cell culture medium and application thereof | |
| CN105695405A (en) | CIK (cytokine-induced killer) cell amplification method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 518057, room 2, building 10, Shenzhen biological incubation center, No. 302, Nanshan District hi tech, Shenzhen, Guangdong Applicant after: ISTEM REGENERATIVE MEDICINE SCI-TECH CO., LTD. Address before: 518057, Guangdong Province, Nanshan District high tech Zone, South Ring Road, No. 29, No. 02 building, international students, building No. 15 Applicant before: ISTEM REGENERATIVE MEDICINE SCI-TECH CO., LTD. |
|
| COR | Change of bibliographic data | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160629 |